| 49.985 1.032 (2.11%) | 06-15 13:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 60.03 | 1-year : | 70.12 |
| Resists | First : | 51.4 | Second : | 60.03 |
| Pivot price | 48.78 |
|||
| Supports | First : | 46.61 | Second : | 43.65 |
| MAs | MA(5) : | 49 |
MA(20) : | 47.9 |
| MA(100) : | 46.21 |
MA(250) : | 42.5 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 59.2 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 51.41 | Low : | 31.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GNOM ] has closed below upper band by 15.0%. Bollinger Bands are 18.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.69 - 49.93 | 49.93 - 50.13 |
| Low: | 48.1 - 48.43 | 48.43 - 48.71 |
| Close: | 48.49 - 48.99 | 48.99 - 49.4 |
The Global X Genomics & Biotechnology ETF, known by its ticker GNOM, aims to closely track the performance of the Solactive Genomics Index, reflecting both its price appreciation and any generated income. This mirroring occurs before the deduction of the ETF's internal fees and expenses.
Mon, 11 May 2026
Best CRISPR Gene Editing ETFs for 2026 and How to Invest - The Motley Fool
Fri, 20 Mar 2026
Biotech stocks and longevity investing: Trends to track - Stacker
Mon, 16 Mar 2026
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave - TradingView
Wed, 11 Feb 2026
7 Best Biotech ETFs to Buy Now | Investing - U.S. News - Money
Fri, 28 Nov 2025
Unveiling the global urban virome through wastewater metagenomics - Nature
Thu, 28 Aug 2025
Investing in the DNA of Tomorrow: Explore Gene Stocks and Genomics ETFs - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management - Global
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|